The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis
- PMID: 11712757
- DOI: 10.1016/s1471-4892(01)00055-8
The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis
Abstract
The collagenases of the matrix metalloproteinase family are key enzymes in mediating irreversible cartilage collagen loss in arthritis. Inhibition of these enzymes is, therefore, an important therapeutic target. New approaches to collagenase inhibition include active site inhibitors designed for specific enzymes, inhibition of cell signalling molecules and transcription factors involved in collagenase gene expression, prevention of zymogen activation and induction of natural inhibitor production.
Similar articles
-
Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis.Expert Opin Investig Drugs. 2000 Jul;9(7):1469-78. doi: 10.1517/13543784.9.7.1469. Expert Opin Investig Drugs. 2000. PMID: 11060752 Review.
-
Cannabinoids: novel therapies for arthritis?Future Med Chem. 2012 Apr;4(6):713-25. doi: 10.4155/fmc.12.20. Future Med Chem. 2012. PMID: 22530636 Review.
-
Suppressive effects of the new antirheumatic drug KE-298 on TNF alpha-induced production of matrix metalloproteinases but not of tissue inhibitor-1 of metalloproteinases in human rheumatoid synoviocytes.Drugs Exp Clin Res. 1998;24(2):67-71. Drugs Exp Clin Res. 1998. PMID: 9675546
-
Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis.Lab Invest. 1994 Jun;70(6):807-15. Lab Invest. 1994. PMID: 8015285
-
Design strategies for the identification of MMP-13 and Tace inhibitors.Curr Opin Drug Discov Devel. 2003 Sep;6(5):742-59. Curr Opin Drug Discov Devel. 2003. PMID: 14579524 Review.
Cited by
-
Drugs in development: bisphosphonates and metalloproteinase inhibitors.Arthritis Res Ther. 2003;5(1):12-24. doi: 10.1186/ar604. Epub 2002 Nov 8. Arthritis Res Ther. 2003. PMID: 12716443 Free PMC article. Review.
-
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.Arthritis Res Ther. 2007;9(5):R109. doi: 10.1186/ar2315. Arthritis Res Ther. 2007. PMID: 17958901 Free PMC article. Clinical Trial.
-
Mithramycin downregulates proinflammatory cytokine-induced matrix metalloproteinase gene expression in articular chondrocytes.Arthritis Res Ther. 2005;7(4):R777-83. doi: 10.1186/ar1735. Epub 2005 Apr 4. Arthritis Res Ther. 2005. PMID: 15987479 Free PMC article.
-
Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.PLoS One. 2017 Dec 18;12(12):e0189701. doi: 10.1371/journal.pone.0189701. eCollection 2017. PLoS One. 2017. PMID: 29253870 Free PMC article.
-
Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography.Ann Rheum Dis. 2006 Apr;65(4):501-7. doi: 10.1136/ard.2005.039032. Epub 2005 Sep 8. Ann Rheum Dis. 2006. PMID: 16150790 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical